RB1 and cancer: E2F activity, as defined by expression of E2F target genes, is high in virtually all cancers, often owing to inactivation of its main binding partner and key regulator, RB (encoded by RB1), overexpression of cyclin-dependent kinases (CDKs) or inactivation of CDK inhibitors (77–79).